SVB Leerink Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $54
SVB Leerink analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $56 to $54.
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers Cosmos Holdings (NASDAQ:COSM) stock increased by 20.5% to $0.52 during Monday’s pre-market session. The company’s market cap…
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Gainers
Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday.
Jim Cramer Says ‘There’s Too Much Political Risk’ For This Stock Is Up 106% In 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Rocket Pharmaceuticals Inc (NASDAQ: RCKT) is a "very early stage company that has a lot in the pipe. I tend to like these companies."
Canaccord Genuity Initiates Coverage On Rocket Pharmaceuticals with Buy Rating, Announces Price Target of $53
Canaccord Genuity analyst Whitney Ijem initiates coverage on Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy rating and announces Price Target of $53.
Raymond James Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $33
Raymond James analyst Steven Seedhouse maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $34 to $33.
Needham Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $60
Needham analyst Gil Blum maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target from $62 to $60.
Rocket Pharmaceuticals Priced 6.*M Share Public Offering of Common Stock @ $14.75/Share
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced the pricing of an underwritten public offering of 6,800,000 shares of its common stock at a public offering price of $14.75 per share.
Rocket Pharmaceuticals Announces Proposed Public Offering Of $100M Of Shares Of Its Common Stock
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of investigational genetic therapies for rare childhood disorders with high